West Pharmaceutical
About: West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Employees: 10,600
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
56% more call options, than puts
Call options by funds: $98M | Put options by funds: $63M
3% more repeat investments, than reductions
Existing positions increased: 266 | Existing positions reduced: 259
1.09% less ownership
Funds ownership: 96.18% [Q4 2024] → 95.1% (-1.09%) [Q1 2025]
5% less funds holding
Funds holding: 734 [Q4 2024] → 699 (-35) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 111
33% less capital invested
Capital invested by funds: $22.8B [Q4 2024] → $15.4B (-$7.44B) [Q1 2025]
70% less funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 3 (-7) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$245
8%
upside
Avg. target
$245
8%
upside
High target
$245
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Barclays Luke Sergott | 8%upside $245 | Equal-Weight Initiated | 24 Jun 2025 |
Financial journalist opinion
Based on 110 articles about WST published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
WEST ALERT: Bragar Eagel & Squire, P.C. is Investigating West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (NYSE:WST) on behalf of long-term stockholders following a class action complaint that was filed against West on June 20, 2025 with a Class Period from February 16, 2023 and February 12, 2025. Our investigation concerns whether the board of directors of West have breached their fiduciary duties to the company.
Neutral
PRNewsWire
3 days ago
West to Host Second-Quarter 2025 Conference Call
EXTON, Pa. , July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
Neutral
GlobeNewsWire
4 days ago
West Pharmaceutical Services, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 7, 2025 to Discuss Your Rights – WST
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).
Neutral
PRNewsWire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
Business Wire
4 days ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
NEW YORK--(BUSINESS WIRE)---- $WST #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. T.
Neutral
PRNewsWire
4 days ago
WST Investors Have Opportunity to Lead West Pharmaceutical Services, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , July 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 7, 2025.
Neutral
PRNewsWire
4 days ago
Class Action Filed Against West Pharmaceutical Services, Inc. (WST) Seeking Recovery for Investors - Contact The Gross Law Firm
NEW YORK , July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
5 days ago
WST Shareholders Have the Right to Lead the West Pharmaceutical Services, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - WST
LOS ANGELES , July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) for violations of the federal securities laws. Shareholders who purchased the Company's securities between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 7, 2025.
Neutral
GlobeNewsWire
5 days ago
WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) and certain of its officers.
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Charts implemented using Lightweight Charts™